Shigellosis is a form of bacterial diarrhea caused by gram-negative bacteria Shigella species. It is common in developing countries and results from contaminated food, poor sanitation conditions, or direct person to person contact. Shigella can cause infection in all age groups. High-risk group include very young, elderly, and immunocompromised person. Shigella species is relatively resistant to acid in the stomach, and few organisms are required to cause the disease. Once ingested, it multiplies in the small intestine and enters the colon. In the colon, it produces shigella enterotoxins and serotype toxin 1, resulting in watery or bloody diarrhea. Clinical manifestations usually result within 12 hours to 3 days of ingestion of the organism with an average incubation period of 3 days. These symptoms include high fever, vomiting, diffuse colicky abdominal pain followed by bloody mucoid diarrhea and tenesmus. It self-resolves within 5 to 7 days of onset of symptoms. However, high-risk individuals may end up with complications.
Shigellosis is a food-borne or water-borne illness caused by Shigella. Shigella is a gram-negative, nonmotile, facultatively anaerobic, non-spore-forming rod. It has 4 serotypes:
Shigella sonnei is different from the other serotypes by the expression of ornithine decarboxylase while serotypes A, B and C cannot be differentiated with any biochemical marker.
The incidence of shigellosis is reported to be one hundred eighty-eight million cases per year with approximately 1 million deaths annually. In developed countries, the incidence is around 1.5 million cases per year. In the United States, it results in about 450,000 cases annually. Most cases reported in the United States are caused by S. sonnei (77%). The serotype responsible for mainly causing disease in developing countries is S. flexneri. It is more common in young children with most cases reported in children (28 cases/100,000 in children) younger than 4 years and 25 cases/100,000 in 4 to 11-year-olds). Shigella is the most common cause of diarrheal illness in children younger than 5 years old in Saharan Africa and South Asia. There is no gender predominance and racial predilection for shigellosis.
Shigellosis is common in daycare centers and residential institutions in the United States. Foodborne transmission has also been reported in the United States. Outbreaks of shigellosis have also occurred in men who have sex with men.
Route of Transmission
The path of transmission of shigellosis is mostly via the fecal-oral route in developed countries and fecal-oral route, water-borne or food-borne in developing countries.  However, it can also be transmitted sexually especially in men who have sex with men   or by flies. Humans are the only natural reservoir for shigella.
Size of Inoculum
The number of organisms required to cause the disease is usually 10 to 200 due to the low sensitivity to stomach acid and downregulation of antibacterial proteins of the host by the organism.
Once ingested, Shigella enters the small intestine and multiplies then enters the large intestine. Shigella causes cell injury and resulting complications by direct invasion of colonic mucosa and production of enterotoxins.
Direct Invasion of Epithelial Cells
In the large intestine, it invades using transcytosis and transports through basolateral epithelium using M cells which are mainly responsible for immune activation of intestinal lymphoid tissue by antigen recognition. Following transcytosis, it induces macrophages and cellular apoptosis. This results in the release of inflammatory cytokines such as IL-1 and IL-18 which results in intestinal inflammation and subsequent activation of the innate immune system. Shigella is released from the macrophages after following apoptosis and inflammation. It continues to invade the adjacent epithelium and the immune system by using the intercellular actin polymerization process. As Shigella invades the epithelial cells, it activates nuclear factor (kappa B) in the cells causing the production of IL-8 which stimulates recruitment of neutrophils at the site causing more inflammation and epithelial damage. It causes impaired absorption of nutrients causing diarrhea.
Another mechanism for cell injury by Shigella is through the production of enterotoxin 1 and 2 which plays a part in impaired fluid and nutrient absorption causing Shigella-associated diarrhea. Cytotoxin Shigella dysenteriae serotype 1 is responsible for cytotoxicity and vascular lesions in the colon and other organs such as kidneys causing bloody diarrhea and complications such as hemolytic uremic syndrome (HUS).
Microscopic examination of the infected tissue such as colon, rectum, or distal ileum may result in the following findings including polymorphonuclear cells infiltration of the epithelial cells, and the formation of inflammatory patch pseudomembranes. Shigella multiplies in the colonic epithelium leading to cell death. It then spreads laterally to infect and kill adjacent epithelium causing ulceration of mucosa which leads to inflammation and bleeding.
Common symptoms may include mild abdominal discomfort to severe diffuse colicky abdominal pain (70% to 90%). Patient reports of small volume mucoid diarrhea (70% to 80%) that precedes bloody diarrhea (30% to 50%). Other symptoms include fever, nausea, vomiting, anorexia, lethargy, and tenesmus. Rare but severe symptoms include delirium, encephalopathy, anuria, seizures, meningismus, and coma.
Physical examination of patients suffering from shigellosis may indicate lethargic or toxic individuals. Vital signs may reveal fever, tachycardia, tachypnea, and hypotension. An abdominal examination may show a distended abdomen with hyperactive bowel sounds. Tenderness may be present especially in the lower abdomen due to the involvement of sigmoid colon and rectum.
The mainstay of treatment of shigellosis is medical management and includes hydration and electrolyte management. Oral rehydration might be adequate in many cases.
In adults, the choice of empiric antibiotics is based on demographics and regional resistance. Fluoroquinolone is recommended for patients with no risk factors for resistance while a third-generation cephalosporin is recommended in high-risk patients including infected patients in Africa and Asia, international travelers, HIV-infected patients and men having sex with men. Antibiotics should be changed once susceptibility result is available. Second-generation cephalosporin, ampicillin, and trimethoprim-sulfamethoxazole can also be used for the treatment of Shigella infection if susceptibility is documented.
In pediatrics, the first-line drug is azithromycin if antibiotic susceptibility is unknown. In a randomized trial, Azithromycin was found to be clinically and bacteriological successful in 82% and 94% of patients treated respectively. Cefixime and ceftibuten can be used as first-line to treat shigellosis in South Asia due to widespread resistance to commonly used antibiotics. The alternative regimen includes pivmecillinam, an extended-spectrum penicillin is effective in decreasing diarrhea duration and eradication of shigella organisms in the stool.
Parenteral antibiotics are indicated in children with suspected and proven shigellosis who have a severe infection with signs of bacteremia including lethargy, temperature >39° C (102.2°F), underlying immune deficiency including AIDS and those unable to take oral medications. Ceftriaxone is recommended as a single dose or for five days.
Frequent handwashing with soap and water is recommended especially after bathroom use and before food preparation. Food handlers should not engage in food preparation if stool cultures remain positive. Usually, conversion to negative stool cultures occurs about 2 days after initiation of antibiotic therapy.
Differential diagnosis of shigellosis include infection with the following organisms due to overlapping symptoms of fever, nausea, vomiting and abdominal pain:
Other diseases causing chronic diarrhea which might be differentiated include:
If diagnosed and treated on time, the prognosis of shigellosis is good, and patients recover without sequelae. However, certain poor prognostic factors include a delay in treatment, immunocompromised state, prolonged duration of disease (more than 7 days), and extremes of age such as elderly and very young individuals can lead to severe disease and complications.
Complications of shigella infection include intestinal and systemic complications listed below. 
There is no vaccine to prevent shigellosis. However, the disease can be limited by practicing certain precautions:
The diagnosis of shigellosis often takes time and the infection can be confused with many other abdominal conditions. Thus, it is best managed by an interprofessional team that includes the emergency department physician, infectious disease specialist, gastroenterologist, and internist. The mainstay of treatment of shigellosis is medical management and includes fluid and electrolyte management. The antibiotic regimen used for the treatment can be divided into two groups based on age. Antibiotic susceptibility testing is highly recommended before as resistance to the drugs is common and may vary regionally. Immunity can occur after shigella infection and appears to be serotype-specific.
Because there is no vaccine to prevent the infection, the primary care provider and nurse specialist play a vital role in educating the public about prevention. This includes handwashing with soap and water, maintaining good personal hygiene, drinking boiled water while traveling and avoiding sexual contact with a patient with a recent diagnosis of shigellosis.
The outlook for patients who are treated promptly is good but delays in treatment can lead to multiorgan failure and even death. Confirmed cases of shigellosis in the United States should be reported to the Centers for Disease Control and Prevention via state or local health department.
|||Inoculum size in shigellosis and implications for expected mode of transmission., DuPont HL,Levine MM,Hornick RB,Formal SB,, The Journal of infectious diseases, 1989 Jun [PubMed PMID: 2656880]|
|||Epidemiologic and clinical features of patients infected with Shigella who attended a diarrheal disease hospital in Bangladesh., Stoll BJ,Glass RI,Huq MI,Khan MU,Banu H,Holt J,, The Journal of infectious diseases, 1982 Aug [PubMed PMID: 7108270]|
|||Barrett-Connor E,Connor JD, Extraintestinal manifestations of shigellosis. The American journal of gastroenterology. 1970 Mar; [PubMed PMID: 5435635]|
|||Microbiology and diagnosis of infections with Shigella and enteroinvasive Escherichia coli., Echeverria P,Sethabutr O,Pitarangsi C,, Reviews of infectious diseases, 1991 Mar-Apr [PubMed PMID: 2047641]|
|||Gastrointestinal and extra-intestinal manifestations of childhood shigellosis in a region where all four species of Shigella are endemic., Khan WA,Griffiths JK,Bennish ML,, PloS one, 2013 [PubMed PMID: 23691156]|
|||McCrickard LS,Crim SM,Kim S,Bowen A, Disparities in severe shigellosis among adults - Foodborne diseases active surveillance network, 2002-2014. BMC public health. 2018 Feb 7 [PubMed PMID: 29415691]|
|||Kotloff KL,Riddle MS,Platts-Mills JA,Pavlinac P,Zaidi AKM, Shigellosis. Lancet (London, England). 2018 Feb 24; [PubMed PMID: 29254859]|
|||Liu J,Platts-Mills JA,Juma J,Kabir F,Nkeze J,Okoi C,Operario DJ,Uddin J,Ahmed S,Alonso PL,Antonio M,Becker SM,Blackwelder WC,Breiman RF,Faruque AS,Fields B,Gratz J,Haque R,Hossain A,Hossain MJ,Jarju S,Qamar F,Iqbal NT,Kwambana B,Mandomando I,McMurry TL,Ochieng C,Ochieng JB,Ochieng M,Onyango C,Panchalingam S,Kalam A,Aziz F,Qureshi S,Ramamurthy T,Roberts JH,Saha D,Sow SO,Stroup SE,Sur D,Tamboura B,Taniuchi M,Tennant SM,Toema D,Wu Y,Zaidi A,Nataro JP,Kotloff KL,Levine MM,Houpt ER, Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. Lancet (London, England). 2016 Sep 24 [PubMed PMID: 27673470]|
|||MOSLEY WH,ADAMS B,LYMAN ED, Epidemiologic and sociologic features of a large urban outbreak of shigellosis. JAMA. 1962 Dec 29 [PubMed PMID: 13936184]|
|||Painter JA,Hoekstra RM,Ayers T,Tauxe RV,Braden CR,Angulo FJ,Griffin PM, Attribution of foodborne illnesses, hospitalizations, and deaths to food commodities by using outbreak data, United States, 1998-2008. Emerging infectious diseases. 2013 Mar [PubMed PMID: 23622497]|
|||Shigella flexneri serotype 3 infections among men who have sex with men--Chicago, Illinois, 2003-2004. MMWR. Morbidity and mortality weekly report. 2005 Aug 26 [PubMed PMID: 16121121]|
|||Hines JZ,Pinsent T,Rees K,Vines J,Bowen A,Hurd J,Leman RF,Hedberg K, Notes from the Field: Shigellosis Outbreak Among Men Who Have Sex with Men and Homeless Persons - Oregon, 2015-2016. MMWR. Morbidity and mortality weekly report. 2016 Aug 12 [PubMed PMID: 27513523]|
|||Niyogi SK, Shigellosis. Journal of microbiology (Seoul, Korea). 2005 Apr; [PubMed PMID: 15880088]|
|||[PubMed PMID: 26042652]|
|||Mathan MM,Mathan VI, Morphology of rectal mucosa of patients with shigellosis. Reviews of infectious diseases. 1991 Mar-Apr [PubMed PMID: 2047656]|
|||Zychlinsky A,Thirumalai K,Arondel J,Cantey JR,Aliprantis AO,Sansonetti PJ, In vivo apoptosis in Shigella flexneri infections. Infection and immunity. 1996 Dec [PubMed PMID: 8945588]|
|||Mathan VI,Mathan MM, Intestinal manifestations of invasive diarrheas and their diagnosis. Reviews of infectious diseases. 1991 Mar-Apr [PubMed PMID: 2047655]|
|||Sur D,Ramamurthy T,Deen J,Bhattacharya SK, Shigellosis : challenges [PubMed PMID: 15591629]|
|||[PubMed PMID: 17881877]|
|||Ferrera PC,Jeanjaquet MS,Mayer DM, Shigella-induced encephalopathy in an adult. The American journal of emergency medicine. 1996 Mar [PubMed PMID: 8924141]|
|||Fried D,Maytal J,Hanukoglu A, The differential leukocyte count in shigellosis. Infection. 1982 Jan [PubMed PMID: 7068229]|
|||Halpern Z,Averbuch M,Dan M,Giladi M,Levo Y, The differential leukocyte count in adults with acute gastroenteritis. Scandinavian journal of infectious diseases. 1992 [PubMed PMID: 1641598]|
|||[PubMed PMID: 1094073]|
|||Bennish ML, Potentially lethal complications of shigellosis. Reviews of infectious diseases. 1991 Mar-Apr [PubMed PMID: 2047657]|
|||Keusch GT,Bennish ML, Shigellosis: recent progress, persisting problems and research issues. The Pediatric infectious disease journal. 1989 Oct [PubMed PMID: 2682504]|
|||Martin T,Habbick BF,Nyssen J, Shigellosis with bacteremia: a report of two cases and a review of the literature. Pediatric infectious disease. 1983 Jan-Feb [PubMed PMID: 6340078]|
|||Struelens MJ,Patte D,Kabir I,Salam A,Nath SK,Butler T, Shigella septicemia: prevalence, presentation, risk factors, and outcome. The Journal of infectious diseases. 1985 Oct [PubMed PMID: 4045231]|
|||Davies NE,Karstaedt AS, Shigella bacteraemia over a decade in Soweto, South Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008 Dec [PubMed PMID: 18550134]|
|||Bennish ML,Salam MA,Wahed MA, Enteric protein loss during shigellosis. The American journal of gastroenterology. 1993 Jan [PubMed PMID: 8420274]|
|||DuPont HL,Hornick RB, Adverse effect of lomotil therapy in shigellosis. JAMA. 1973 Dec 24 [PubMed PMID: 4587313]|
|||Heiman KE,Karlsson M,Grass J,Howie B,Kirkcaldy RD,Mahon B,Brooks JT,Bowen A, Notes from the field: Shigella with decreased susceptibility to azithromycin among men who have sex with men - United States, 2002-2013. MMWR. Morbidity and mortality weekly report. 2014 Feb 14 [PubMed PMID: 24522098]|
|||Khan WA,Seas C,Dhar U,Salam MA,Bennish ML, Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Annals of internal medicine. 1997 May 1 [PubMed PMID: 9139555]|
|||Rahman M,Shoma S,Rashid H,El Arifeen S,Baqui AH,Siddique AK,Nair GB,Sack DA, Increasing spectrum in antimicrobial resistance of Shigella isolates in Bangladesh: resistance to azithromycin and ceftriaxone and decreased susceptibility to ciprofloxacin. Journal of health, population, and nutrition. 2007 Jun [PubMed PMID: 17985817]|
|||Salam MA,Dhar U,Khan WA,Bennish ML, Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet (London, England). 1998 Aug 15 [PubMed PMID: 9716056]|
|||[PubMed PMID: 20348130]|
|||Azad MA,Islam M,Butler T, Colonic perforation in Shigella dysenteriae 1 infection. Pediatric infectious disease. 1986 Jan-Feb [PubMed PMID: 3511451]|
|||Bennish ML,Azad AK,Yousefzadeh D, Intestinal obstruction during shigellosis: incidence, clinical features, risk factors, and outcome. Gastroenterology. 1991 Sep [PubMed PMID: 1860627]|
|||Siegler RL, The hemolytic uremic syndrome. Pediatric clinics of North America. 1995 Dec [PubMed PMID: 8614598]|
|||[PubMed PMID: 6695872]|
|||Ashkenazi S,Dinari G,Zevulunov A,Nitzan M, Convulsions in childhood shigellosis. Clinical and laboratory features in 153 children. American journal of diseases of children (1960). 1987 Feb [PubMed PMID: 3544808]|
|||Khan WA,Dhar U,Salam MA,Griffiths JK,Rand W,Bennish ML, Central nervous system manifestations of childhood shigellosis: prevalence, risk factors, and outcome. Pediatrics. 1999 Feb [PubMed PMID: 9925864]|
|||Porter CK,Choi D,Riddle MS, Pathogen-specific risk of reactive arthritis from bacterial causes of foodborne illness. The Journal of rheumatology. 2013 May [PubMed PMID: 23547220]|
|||[PubMed PMID: 375177]|
|||Tobias JD,Starke JR,Tosi MF, Shigella keratitis: a report of two cases and a review of the literature. The Pediatric infectious disease journal. 1987 Jan [PubMed PMID: 3547292]|
|||Rubenstein JS,Noah ZL,Zales VR,Shulman ST, Acute myocarditis associated with Shigella sonnei gastroenteritis. The Journal of pediatrics. 1993 Jan [PubMed PMID: 7678291]|
|||Taylor DN,Bodhidatta L,Brown JE,Echeverria P,Kunanusont C,Naigowit P,Hanchalay S,Chatkaeomorakot A,Lindberg AA, Introduction and spread of multi-resistant Shigella dysenteriae I in Thailand. The American journal of tropical medicine and hygiene. 1989 Jan [PubMed PMID: 2644859]|
|||[PubMed PMID: 8569531]|
|||Keren DF,Kern SE,Bauer DH,Scott PJ,Porter P, Direct demonstration in intestinal secretions of an IgA memory response to orally administered Shigella flexneri antigens. Journal of immunology (Baltimore, Md. : 1950). 1982 Jan [PubMed PMID: 7033378]|
|||Rasolofo-Razanamparany V,Cassel-Beraud AM,Roux J,Sansonetti PJ,Phalipon A, Predominance of serotype-specific mucosal antibody response in Shigella flexneri-infected humans living in an area of endemicity. Infection and immunity. 2001 Sep [PubMed PMID: 11500390]|
|||Wilmer A,Romney MG,Gustafson R,Sandhu J,Chu T,Ng C,Hoang L,Champagne S,Hull MW, Shigella flexneri serotype 1 infections in men who have sex with men in Vancouver, Canada. HIV medicine. 2015 Mar; [PubMed PMID: 25656740]|
|||Das JK,Tripathi A,Ali A,Hassan A,Dojosoeandy C,Bhutta ZA, Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus. BMC public health. 2013; [PubMed PMID: 24564510]|
|||Baker KS,Dallman TJ,Field N,Childs T,Mitchell H,Day M,Weill FX,Lefèvre S,Tourdjman M,Hughes G,Jenkins C,Thomson N, Horizontal antimicrobial resistance transfer drives epidemics of multiple Shigella species. Nature communications. 2018 Apr 13; [PubMed PMID: 29654279]|